HK1093314A1 - Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens - Google Patents

Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens

Info

Publication number
HK1093314A1
HK1093314A1 HK06114232.3A HK06114232A HK1093314A1 HK 1093314 A1 HK1093314 A1 HK 1093314A1 HK 06114232 A HK06114232 A HK 06114232A HK 1093314 A1 HK1093314 A1 HK 1093314A1
Authority
HK
Hong Kong
Prior art keywords
bordetella
induces
cell responses
adenylate cyclase
responses against
Prior art date
Application number
HK06114232.3A
Other languages
English (en)
Inventor
Gilles Dadaglio
Claude Leclerc
Daniel Ladant
Eynde Benoit Van Den
Sandra Morel
Cecile Bauche
Original Assignee
Centre Nat Rech Scient
I N S E R M Inst Nat De La San
Pasteur Institut
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, I N S E R M Inst Nat De La San, Pasteur Institut, Ludwig Inst Cancer Res filed Critical Centre Nat Rech Scient
Publication of HK1093314A1 publication Critical patent/HK1093314A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C25/00—Bearings for exclusively rotary movement adjustable for wear or play
    • F16C25/06—Ball or roller bearings
    • F16C25/08—Ball or roller bearings self-adjusting
    • F16C25/083—Ball or roller bearings self-adjusting with resilient means acting axially on a race ring to preload the bearing
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C27/00—Elastic or yielding bearings or bearing supports, for exclusively rotary movement
    • F16C27/06—Elastic or yielding bearings or bearing supports, for exclusively rotary movement by means of parts of rubber or like materials
    • F16C27/066—Ball or roller bearings
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C33/00—Parts of bearings; Special methods for making bearings or parts thereof
    • F16C33/72—Sealings
    • F16C33/76—Sealings of ball or roller bearings
    • F16C33/78—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members
    • F16C33/7886—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members mounted outside the gap between the inner and outer races, e.g. sealing rings mounted to an end face or outer surface of a race
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C19/00—Bearings with rolling contact, for exclusively rotary movement
    • F16C19/02—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows
    • F16C19/04—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly
    • F16C19/06—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly with a single row or balls

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HK06114232.3A 2003-11-21 2006-12-28 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens HK1093314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52363203P 2003-11-21 2003-11-21
PCT/EP2004/014086 WO2005053738A1 (fr) 2003-11-21 2004-11-19 Toxine d'adenylate-cyclase recombinante de bordetella induisant des reponses des lymphocytes t contre des antigenes tumoraux

Publications (1)

Publication Number Publication Date
HK1093314A1 true HK1093314A1 (en) 2007-03-02

Family

ID=34652257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06114232.3A HK1093314A1 (en) 2003-11-21 2006-12-28 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens

Country Status (11)

Country Link
US (4) US20050271679A1 (fr)
EP (2) EP1684801B1 (fr)
JP (1) JP4976853B2 (fr)
AT (1) ATE450272T1 (fr)
CA (1) CA2546452C (fr)
DE (1) DE602004024440D1 (fr)
ES (1) ES2337694T3 (fr)
HK (1) HK1093314A1 (fr)
PL (1) PL1684801T3 (fr)
PT (1) PT1684801E (fr)
WO (1) WO2005053738A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
WO2005053738A1 (fr) 2003-11-21 2005-06-16 Institut Pasteur Toxine d'adenylate-cyclase recombinante de bordetella induisant des reponses des lymphocytes t contre des antigenes tumoraux
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
US9486524B2 (en) 2006-09-01 2016-11-08 Genticel Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
EP1894941A1 (fr) * 2006-09-01 2008-03-05 Institut Pasteur Traitment du carcinome du col de l'utérus avec une adenylate cyclase portant des antigenes HPV
US9017681B2 (en) * 2007-01-12 2015-04-28 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for antibactrial interventions
CN101680026A (zh) * 2007-01-12 2010-03-24 康乃尔研究基金会有限公司 作为真核病原体感染治疗的新型靶的腺苷酰环化酶
EP2478915A1 (fr) * 2011-01-24 2012-07-25 Genticel Polypeptide(s) transporté(s) par CYAA et utilisation pour induire des réponses immunes tant thérapeutiques que prophylactiques
US9345755B2 (en) * 2012-02-20 2016-05-24 University Of Virginia Patent Foundation Composition and methods for treating melanoma
EP2690172A1 (fr) 2012-07-23 2014-01-29 Genticel Protéines chimériques à base de CYAA comprenant un polypeptide hétérologue et leurs utilisations dans l'induction de réponses immunitaires
WO2017013421A1 (fr) 2015-07-20 2017-01-26 Virttu Biologics Limited Traitement du cancer par perfusion du virus de l'herpès simplex oncolytique dans le sang

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
EP0637335B1 (fr) 1992-04-21 2007-07-25 Institut Pasteur Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO2000067761A1 (fr) 1999-05-06 2000-11-16 Wake Forest University Compositions et procedes d'identification d'antigenes provoquant une reponse immunitaire
CA2386088A1 (fr) * 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Peptides antigeniques mage-a12 et utilisation
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
PT1188446E (pt) * 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (fr) * 2003-06-18 2004-12-22 Institut Pasteur Adényl cyclase de Bordetella modifié avec ou sans le CD11b/CD18 domaine d'interaction et son utilisations
WO2005053738A1 (fr) 2003-11-21 2005-06-16 Institut Pasteur Toxine d'adenylate-cyclase recombinante de bordetella induisant des reponses des lymphocytes t contre des antigenes tumoraux

Also Published As

Publication number Publication date
CA2546452C (fr) 2015-01-20
WO2005053738A1 (fr) 2005-06-16
US9410139B2 (en) 2016-08-09
PL1684801T3 (pl) 2010-07-30
ATE450272T1 (de) 2009-12-15
PT1684801E (pt) 2010-03-08
CA2546452A1 (fr) 2005-06-16
EP2193804A3 (fr) 2010-06-30
EP1684801A1 (fr) 2006-08-02
EP2193804B1 (fr) 2015-12-23
JP2007511233A (ja) 2007-05-10
US20050271679A1 (en) 2005-12-08
ES2337694T3 (es) 2010-04-28
US20140227323A1 (en) 2014-08-14
EP2193804A2 (fr) 2010-06-09
JP4976853B2 (ja) 2012-07-18
DE602004024440D1 (de) 2010-01-14
EP1684801B1 (fr) 2009-12-02
US20100310594A1 (en) 2010-12-09
US20090117143A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
PL347977A1 (en) Novel methods for therapeutic vaccination
WO2008026071A3 (fr) Thérapie du cancer basée sur un composant adaptatif, inné et/ou régulateur de la réponse immunitaire
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
TR199801722T2 (xx) Peptit imm�nojenler.
ATE272113T1 (de) Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
PT1198250E (pt) Proteínas de fusão fc para aumentar a imunogenicidade de antigénios de proteínas e péptidos
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
AU2002245756A1 (en) Identification and modification of immunodominant epitopes in polypeptides
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
DE69131829D1 (de) Gp75 als tumorimpfstoff gegen melanome
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
TNSN08184A1 (en) Chimeric antigens and vaccines
FI854839A (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
ES2199047A1 (es) Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana
DE60325586D1 (de) Mycobakterielle Proteinantigene für Krebstherapie und Impfung
WO2002014352A3 (fr) Composes therapeutiques contre le cancer des ovaires
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
TH59159B (th) สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181122